Colchicine revisited

Research output: Chapter in Book/Report/Conference proceedingConference contribution

46 Scopus citations

Abstract

Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages766-773
Number of pages8
Volume1173
DOIs
StatePublished - Sep 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)00778923
ISSN (Electronic)17496632

    Fingerprint

Keywords

  • Arthritis
  • Gout
  • Uric acid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bhat, A., Naguwa, S. M., Cheema, G. S., & Gershwin, M. E. (2009). Colchicine revisited. In Annals of the New York Academy of Sciences (Vol. 1173, pp. 766-773). (Annals of the New York Academy of Sciences; Vol. 1173). https://doi.org/10.1111/j.1749-6632.2009.04674.x